Table 2.
First author
Year Country |
Final cohort (male:female), diagnosis and cohort description | Age at diagnosis [years] | Follow-up [years] | Method | Effect of HD-MTX |
---|---|---|---|---|---|
Grönroos et al. 2008 Finland |
28 (12:16); ALL, lymphoma | Median 7.7 (range 1.5–15.4) | Median 6.0 (range 1.0–10.0) | iGFR with 51CR-EDTA or 99mTc-DTPA, urinalysis continuous variables |
8 g/m2/dose vs. 5 g/m2/dose ▪Albuminuria: no sign. association with its occurrence (OR 1.50, 95%CI 0.29–0.78‡) ▪Proteinuria: no sign. association with its occurrence (OR 4.67, 95%CI 0.42–52.12) |
Study group: ▪Group I: HD-MTX (n = 28) 5 g/m2/dose: n = 16 8 g/m2/dose: n = 12 |
Follow-up: since end of treatment |
Definition: ▪iGFR: reduced if iGFR ▪ < 115 ml/min/1.73m2 ▪Urinary albuminuria: abnormal if albumin/creatinine ratio > 2.5 mg/mmol |
8 g/m2/dose vs. 5 g/m2/dose ▪iGFR: no sign. association with reduced iGFR |
||
Higher cumulative dose: ▪iGFR: no sign. association with reduced iGFR ▪Albuminuria: no sign. association with its occurrence ▪Proteinuria: no sign. association with its occurrence | |||||
Mulder et al. 2013 The Netherlands |
1122 (599:523); different tumors | Median 7.6 (range 0.0–17.8) | Median 15.3 (5.0–36.1) | GFR (CKD-EPI formula for adults) continuous variables |
Higher cumulative dose: ▪GFR: no sign. association with reduced GFR |
Study group: ▪Group I: HD-MTX (n = 253) |
Follow-up: since diagnosis |
Definition: ▪GFR reduced if GFR < 90 ml/min/ 1.73m2 |
Exposure: ▪GFR over time: no sign. effect of HD-MTX on deterioration of GFR over time |
ALL acute lymphoblastic leukemia, CI confidence interval, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, GFR glomerular filtration rate, HD-MTX high-dose methotrexate, iGFR isotope glomerular filtration rate, n number, OR odds ratio, sign. significant(ly). ‡Numbers taken from the original article even though OR is not within the 95%CI